TMF completeness issues during sponsor audit – CAPA for GCP system weaknesses
TMF completeness issues may present themselves through various signals during audits. Common indicators include:Click to read the full article.
REGULATORY COMPLIANCE
Investigator oversight gaps during sponsor audit – CAPA for GCP system weaknesses
Recognizing symptoms arising from investigator oversight gaps is crucial. These may manifest through a variety of signals that can alert teams to potential compliance issues:Click to read the full article.
Investigator oversight gaps during clinical trial conduct – inspection observation risk
Recognizing symptoms indicative of investigator oversight gaps is the first step in addressing potential issues. Common signals include:Click to read the full article.
Informed consent deficiencies during sponsor audit – TMF reconstruction strategy
Strategies for Addressing Informed Consent Deficiencies Observed in Sponsor Audits Informed consent deficiencies during sponsor audits can pose serious challenges to clinical trial integrity and regulatory compliance. Inadequacies in informed…